Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2017-02-01 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Artrosstudie för utvärdering av MIV-711: Studien kan fortsätta utan modifiering efter framgångsrik fjärde granskning av säkerhetsdata
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing the continuation of a Phase IIa clinical trial (MIV-711-201) for osteoarthritis after a successful safety review by an independent data monitoring committee. It discusses trial progress, expected data release timelines (Q3 2017, H1 2018), the drug's potential market (DMOAD), and concludes with standard regulatory disclosure language ('Informationen i detta pressmeddelande är sådan som Medivir AB ska offentliggöra enligt EU:s marknadsmissbruksförordning'). This content is a specific update on ongoing research and development, not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a general corporate announcement regarding R&D progress, which fits best under the general 'Regulatory Filings' (RNS) category as a specific regulatory disclosure, or potentially a specialized update if one existed. Given the options, RNS serves as the best fit for a non-standard, mandatory corporate disclosure that isn't explicitly covered by other codes like DIV, CAP, or ER.
2017-02-01 Swedish
Kallelse till extra bolagsstämma i Medivir AB (publ)
AGM Information Classification · 97% confidence The document is titled "Kallelse till extra bolagsstämma i Medivir AB (publ)" which translates to 'Notice of Extraordinary General Meeting in Medivir AB (publ)'. It details the date, location, registration procedures, and the proposed agenda for an Extraordinary General Meeting (EGM). The agenda includes proposals related to capital reduction and bonus issue (fondemission) as part of a voluntary redemption program. This content directly relates to the formal procedures and materials for a shareholder meeting, specifically concerning voting and corporate actions decided therein. While it is a notice for a meeting, the core purpose is to convene shareholders for voting on specific corporate matters, which aligns closely with the scope of an AGM/EGM notice. Since there is no specific code for an EGM notice, and the content is about convening shareholders for voting on corporate actions, it is most closely related to the general category of shareholder meetings and voting materials. Given the options, 'AGM-R' (AGM Information) is the closest fit for a formal meeting notice, although it is an *Extraordinary* General Meeting. It is not a DEF 14A (Remuneration) or DVA (Voting Results), but the notice *leading* to a vote. I will classify it as AGM-R as it is the primary category for General Meeting materials.
2017-01-10 Swedish
Notice of Extraordinary General Meeting of Medivir AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of Extraordinary General Meeting of Medivir AB (publ)". It details the date, location, participation requirements, and the proposed agenda for this meeting. The agenda includes items like the election of the chairman and specific proposals for a voluntary redemption program and a bonus issue, which are typical items requiring shareholder approval at a general meeting. This content strongly aligns with the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) material, which falls under the AGM Information category.
2017-01-10 English
Medivir completes previously announced oncology programs acquisition
M&A Activity Classification · 95% confidence The document announces the completion of an acquisition and immediately follows this announcement with an 'INVITATION TO CONFERENCE CALL AND WEBCAST' detailing the date, time, and participants for an investor call where 'further financial aspects' will be presented. This structure—an announcement followed by details for a call where management discusses results/strategy—is characteristic of an Earnings Release (ER) or a related investor event announcement. Since the text focuses on a specific corporate action (acquisition completion) and sets up a call to discuss financial aspects, it functions as an initial release of material information. However, the primary focus shifts to inviting participants to a call, which strongly aligns with the definition of a Call Transcript (CT) if the transcript were present, or an Earnings Release (ER) if it were summarizing results. Given the context of presenting 'further financial aspects' following a major transaction, and the explicit invitation to an investor call, this is most closely related to the communication surrounding financial performance updates. Since it is an announcement setting up a call rather than the call transcript itself, and it relates to financial updates, ER is a strong candidate. However, the document is fundamentally an announcement about a corporate transaction (acquisition) and the subsequent investor call. If the call were about quarterly results, ER would be perfect. Since it's about an acquisition and future financial presentation, it's a significant corporate event announcement. Given the options, and the fact that it sets up a call where management will present, it is best classified as a Call Transcript (CT) precursor or an Earnings Release (ER) if the call were earnings-related. Since the call is explicitly set up to present 'financial aspects' of the acquired programs, and the document is short and serves to inform investors about an event, it fits best as an announcement related to investor communication. Given the options, and the focus on setting up a call for investors, I will lean towards the category that covers investor communication events. Since it is not the transcript itself, and it's not a standard 10-K or IR, and it's not a dividend notice, the closest fit for an announcement setting up a call to discuss financial details is often grouped with ER or CT. Since the text is an invitation to a call, and not the transcript, I will re-evaluate. It is an announcement of a corporate event (acquisition completion) and an invitation to a call. This doesn't perfectly match ER (which is usually results summary) or CT (which is the transcript). It is a general corporate update related to financing/strategy. Given the options, and the lack of a specific 'Corporate Action Announcement' code, I will check if it fits M&A (TAR) or Capital (CAP). It is the completion of an acquisition, which is M&A activity. The document announces the completion and sets up a call to discuss the financial aspects. Therefore, TAR (M&A Activity) is the most accurate classification for the core event being reported.
2016-12-29 English
Medivir slutför tidigare kommunicerat förvärv av onkologiprogram
M&A Activity Classification · 95% confidence The document announces the completion of an acquisition ('Medivir slutför tidigare kommunicerat förvärv av onkologiprogram') and details a one-time payment made. Crucially, it includes an invitation to a conference call/webcast for analysts and investors to present further financial information about the acquired programs. This structure—announcing a significant corporate action (M&A related) followed immediately by an investor call invitation—is characteristic of a major corporate event announcement. Since the core event is a merger/acquisition activity, the most fitting category is M&A Activity (TAR). While it mentions financial details will be presented later, the primary purpose of this specific document is the announcement of the transaction completion, not the detailed financial report itself (which would be 10-K or IR). It is not a standard Earnings Release (ER) or a general Regulatory Filing (RNS).
2016-12-29 Swedish
Medivir completes the divestment of BioPhausia – a transfer of approx. SEK 870m to the shareholders through a share redemption offer will be proposed
Capital/Financing Update Classification · 95% confidence The document announces the completion of a divestment (BioPhausia) and immediately details the proposed action for the resulting cash proceeds: a transfer of approximately SEK 870m to shareholders via a voluntary share redemption offer, which requires an Extraordinary General Meeting (EGM) resolution. This action directly relates to changing the company's capital structure and returning value to shareholders through a specific financing mechanism (share redemption). This aligns best with the 'Capital/Financing Update' category (CAP), as it is a direct consequence of a major transaction leading to a capital structure change proposal. While it mentions an EGM, the core subject is the capital return proposal, not the voting results (DVA) or the general AGM materials (AGM-R). It is not an ER, IR, or 10-K as it is not a periodic financial report.
2016-12-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.